Psoriasis Clinical Trial

Clinical Trial Finder Psoriasis Trials

Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis

See Locations Near You

Summary

This study is designed to evaluate efficacy, safety, pharmacokinetics (PK) and immunogenicity of subcutaneously administered DMB-3115 in comparison with Stelara for treatment of moderate to severe chronic plaque psoriasis.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients who have a diagnosis of plaque-type psoriasis for at least 6 months.

Exclusion Criteria:

Patients with hypersensitivity to ustekinumab or any of the product excipients.

Study is for people with:

Psoriasis

Phase:

Phase 3

Estimated Enrollment:

598

Study ID:

NCT04785326

Recruitment Status:

Completed

Sponsor:

Dong-A ST Co., Ltd.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Central Sooner Research
Norman Oklahoma, 73071, United States
Jordan Valley Dermatology Center
West Jordan Utah, 84088, United States

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 3

Estimated Enrollment:

598

Study ID:

NCT04785326

Recruitment Status:

Completed

Sponsor:


Dong-A ST Co., Ltd.

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials Can be Life-Saving for Some
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider